New therapies on the horizon for hepatitis C
β Scribed by De Francesco, Raffaele; Rice, Charles M.
- Book ID
- 122511521
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 464 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1089-3261
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
See Articles on Pages 631 and 640. N o challenge in clinical hepatology is as great today as the management of patients with chronic hepatitis C who have failed to respond to an adequate course of antiviral therapy. At present, the optimal regimen is a combination of peginterferon and ribavirin. 1 W
## Abstract Hepatitis C reduces the quality of life for some 170 million people around the globe and is one of the most prevalent diseases on the planet. It is caused by the hepatitis C virus (HCV) that is replicated by an errorβprone polymerase and therefore undergoes rapid evolution. To date, alt